The COVID variant BA.3.2 has emerged as a significant concern worldwide, first identified in South Africa in November 2024. Since then, it has been detected in 29 U.S. states and Puerto Rico, highlighting its rapid spread across various regions.
As of March 12, 2026, BA.3.2 has been identified in nasal swabs from six U.S. travelers, three airplane wastewater samples, 29 patients, and 260 wastewater samples. This variant has approximately 70 to 75 mutations in its spike protein compared to the antigens used in current vaccines, raising alarms about its potential to evade vaccine-induced immunity.
The numbers
The prevalence of BA.3.2 detections among 5,238 sequences collected from December 1, 2025, to March 12, 2026, stands at 0.55%. This variant has been reported by at least 23 countries as of February 11, 2026, and has cocirculated with various JN.1 descendant lineages, with prevalences of approximately 10%–40% in several European countries.
Laboratory studies suggest that BA.3.2 efficiently evades antibodies, potentially reducing vaccine protection. Researchers emphasize that monitoring the spread of BA.3.2 provides valuable information about the potential for this new SARS-CoV-2 lineage to evade immunity from previous infections or vaccinations.
The first identification of BA.3.2 in the U.S. occurred on June 27, 2025, through the Traveler-Based Genomic Surveillance program. Phylogenetic analyses have identified two sublineages of BA.3.2, namely BA.3.2.1 and BA.3.2.2, further complicating the public health response.
The public health impact of COVID-19 remains significant, with an estimated 390,000–550,000 hospitalizations and 45,000–64,000 deaths during the 2024–2025 respiratory virus season. Wastewater surveillance has served as an effective early warning system for BA.3.2, allowing for timely responses to its spread.
Despite the ongoing monitoring efforts, details remain unconfirmed regarding the full impact of BA.3.2 on human health outcomes. Additionally, the extent of its geographic spread may be underestimated due to limited genomic detection capabilities in many countries, underscoring the need for continued genomic surveillance to track SARS-CoV-2 evolution and its potential effects on public health.
